233 related articles for article (PubMed ID: 36510639)
21. Could Fluorescein Staining in Low-Grade Glial Tumors Guide for Peroperative Differentiation of Pathological Types?
Ozden M; Mammadkhanli O; Zaimoglu M; Bayatli E; Bozkurt M
Turk Neurosurg; 2023; 33(5):847-854. PubMed ID: 37309632
[TBL] [Abstract][Full Text] [Related]
22. Suppression of antitumor immune signatures and upregulation of VEGFA as IDH-mutant gliomas progress to higher grade.
Grewal EP; Richardson LGK; Sun J; Ramapriyan R; Martinez-Lage M; Miller JJ; Cahill DP; Choi BD; Curry WT
Neurosurg Focus; 2024 Feb; 56(2):E2. PubMed ID: 38301244
[TBL] [Abstract][Full Text] [Related]
23. HIP1R and vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma.
Felix M; Friedel D; Jayavelu AK; Filipski K; Reinhardt A; Warnken U; Stichel D; Schrimpf D; Korshunov A; Wang Y; Kessler T; Etminan N; Unterberg A; Herold-Mende C; Heikaus L; Sahm F; Wick W; Harter PN; von Deimling A; Reuss DE
Neuro Oncol; 2022 Dec; 24(12):2121-2132. PubMed ID: 35511748
[TBL] [Abstract][Full Text] [Related]
24. The reliability and interobserver reproducibility of T2/FLAIR mismatch in the diagnosis of IDH-mutant astrocytomas.
Yeniçeri İÖ; Yıldız ME; Özduman K; Danyeli AE; Pamir MN; Dinçer A
Diagn Interv Radiol; 2021 Nov; 27(6):796-801. PubMed ID: 34792037
[TBL] [Abstract][Full Text] [Related]
25. Synchronous contralateral low-grade oligodendroglioma and high-grade IDH-mutant astrocytoma.
White B; Filo J; Orrego-Gonzalez E; Schwartz SN; Varma H; Uhlmann EJ; Vega RA
J Neuropathol Exp Neurol; 2023 Nov; 82(12):1048-1050. PubMed ID: 37875098
[No Abstract] [Full Text] [Related]
26. Tumor heterogeneity and tumor-microglia interactions in primary and recurrent IDH1-mutant gliomas.
Blanco-Carmona E; Narayanan A; Hernandez I; Nieto JC; Elosua-Bayes M; Sun X; Schmidt C; Pamir N; Özduman K; Herold-Mende C; Pagani F; Cominelli M; Taranda J; Wick W; von Deimling A; Poliani PL; Rehli M; Schlesner M; Heyn H; Turcan Ş
Cell Rep Med; 2023 Nov; 4(11):101249. PubMed ID: 37883975
[TBL] [Abstract][Full Text] [Related]
27. Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype.
Patel SH; Bansal AG; Young EB; Batchala PP; Patrie JT; Lopes MB; Jain R; Fadul CE; Schiff D
AJNR Am J Neuroradiol; 2019 Jul; 40(7):1149-1155. PubMed ID: 31248860
[TBL] [Abstract][Full Text] [Related]
28. Clinical implications of molecular analysis in diffuse glioma stratification.
Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Fujioka Y; Takigawa K; Funakoshi Y; Suzuki SO; Iwaki T
Brain Tumor Pathol; 2021 Jul; 38(3):210-217. PubMed ID: 34268651
[TBL] [Abstract][Full Text] [Related]
29. IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.
Ammendola S; Broggi G; Barresi V
Histol Histopathol; 2023 Jul; 38(7):739-753. PubMed ID: 36651583
[TBL] [Abstract][Full Text] [Related]
30. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
Anand S; Chatterjee A; Gupta T; Panda P; Moiyadi A; Epari S; Patil V; Krishnatry R; Goda JS; Jalali R
World Neurosurg; 2021 Oct; 154():e176-e184. PubMed ID: 34245877
[TBL] [Abstract][Full Text] [Related]
31. IDH-1 polymorphisms in pilocytic astrocytomas.
Prayson RA
Ann Diagn Pathol; 2019 Dec; 43():151411. PubMed ID: 31677487
[TBL] [Abstract][Full Text] [Related]
32. A review of adult-type diffuse gliomas in the WHO CNS5 classification with special reference to Astrocytoma, IDH-mutant and Oligodendroglioma, IDH-mutant and 1p/19q codeleted.
Santosh V; Rao S
Indian J Pathol Microbiol; 2022 May; 65(Supplement):S14-S23. PubMed ID: 35562130
[TBL] [Abstract][Full Text] [Related]
33. Radiotherapy delays malignant transformation and prolongs survival in patients with IDH-mutant gliomas.
Liu Y; Chen H; Li G; Zhang J; Yao K; Wu C; Li S; Qiu X
Cancer Biol Med; 2022 Nov; 19(10):1477-86. PubMed ID: 36350001
[TBL] [Abstract][Full Text] [Related]
34.
Zhao K; Yu P; Xue Z; Liu J; Yao A; Zhao Y; Yang F; Tian J; Xu B
Acad Radiol; 2020 Jul; 27(7):e159-e167. PubMed ID: 31607471
[TBL] [Abstract][Full Text] [Related]
35. Combining hyperintense FLAIR rim and radiological features in identifying IDH mutant 1p/19q non-codeleted lower-grade glioma.
Li M; Ren X; Chen X; Wang J; Shen S; Jiang H; Yang C; Zhao X; Zhu Q; Cui Y; Lin S
Eur Radiol; 2022 Jun; 32(6):3869-3879. PubMed ID: 35079884
[TBL] [Abstract][Full Text] [Related]
36. Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas.
Jo J; van den Bent MJ; Nabors B; Wen PY; Schiff D
Neuro Oncol; 2022 Jul; 24(7):1035-1047. PubMed ID: 35137214
[TBL] [Abstract][Full Text] [Related]
37. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.
Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A
Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617
[TBL] [Abstract][Full Text] [Related]
38. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
[TBL] [Abstract][Full Text] [Related]
39. National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States.
Ostrom QT; Shoaf ML; Cioffi G; Waite K; Kruchko C; Wen PY; Brat DJ; Barnholtz-Sloan JS; Iorgulescu JB
Neuro Oncol; 2023 Apr; 25(4):799-807. PubMed ID: 35994777
[TBL] [Abstract][Full Text] [Related]
40.
Yoon BH; Park JS; Kang S; Kwon NJ; Lee KS; Kim CY; Choe G
Br J Neurosurg; 2023 Oct; 37(5):1233-1236. PubMed ID: 33095064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]